P-136 Phase I open-label single-arm study of dual targeting BCMA and CD19 FasTCAR-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myelomaJuan Du, Wei Cao, Jing Lu et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 0